Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 01, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB:

TOMDF), a comprehensive medical

diagnostics and related solutions company, today announced that the management

team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief

Executive Officer, will host a conference call on Thursday, December 2nd at

4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a

strategic outlook for the future.

The call information is as


·       Date: 

December 2, 2021

·       Time: 

4:30 p.m. Eastern Standard Time

·       Direct

Dial-in number: (669) 900-6833

·       Meeting

ID: 94945983568

·       Passcode:


This call is being webcast and

can be accessed at

The call will also be available

for replay by accessing

For more information, please

visit For more information on the Company’s CLIA/CAP

certified lab Provista Diagnostics, Inc. please visit

About Todos Medical Ltd.

Founded in Rehovot, Israel with

offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers

life-saving diagnostic solutions for the early detection of a variety of

cancers. In 2021, Todos completed the acquisition of U.S.-based medical

diagnostics company Provista Diagnostics, Inc. to gain rights to its

Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID

testing and Provista’s proprietary commercial-stage Videssa® breast cancer

blood test. The Company’s state-of-the-art and patented Todos Biochemical

Infrared Analyses (TBIA) is a proprietary cancer-screening technology using

peripheral blood analysis that deploys deep examination into cancer’s influence

on the immune system, looking for biochemical changes in blood mononuclear

cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1

and TMB-2, have received a CE mark in Europe. Todos is focused on the

commercialization of Videssa and will bring the TBIA tests to market


Todos has entered into a joint

venture with NLC Pharma targeting diagnostic and testing solutions to address

the COVID-19 pandemic. The Joint-Venture is pursuing the development of

diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors

that target a fundamental reproductive mechanism of coronaviruses. The

Company’s proprietary therapeutic candidate Tollovir is currently in a Phase 2

clinical trial to treat hospitalized COVID-19 patients in Israel, and is

preparing to initiate Phase 2/3 clinical trials for both hospitalized and

non-hospitalized patients in Israel.

Todos is also developing blood

tests for the early detection of neurodegenerative disorders, such as

Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test) is a

diagnostic blood test that determines the ability of peripheral blood

lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic

stimulation that induces them to enter the cell cycle. It is believed that

certain diseases, most notably Alzheimer’s disease, are the result of

compromised cellular machinery that leads to aberrant cell cycle re-entry by

neurons, which then leads to apoptosis. LymPro is unique in the use of

peripheral blood lymphocytes as a surrogate for neuronal cell function,

suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing

certain (COVID-19) testing materials and supplies to CLIA-certified labs in the

United States. The products cover multiple suppliers of PCR testing kits,

extraction kits, automation materials and supplies, as well as COVID-19

antibody and antigen testing kits.

For more information, please


Forward-looking Statements

Certain statements contained in

this press release may constitute forward-looking statements. For example,

forward-looking statements are used when discussing our expected clinical

development programs and clinical trials. These forward-looking statements are

based only on current expectations of management, and are subject to

significant risks and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements, including

the risks and uncertainties related to the progress, timing, cost, and results

of clinical trials and product development programs; difficulties or delays in

obtaining regulatory approval or patent protection for product candidates;

competition from other biotechnology companies; and our ability to obtain

additional funding required to conduct our research, development and

commercialization activities. In addition, the following factors, among others,

could cause actual results to differ materially from those described in the

forward-looking statements: changes in technology and market requirements;

delays or obstacles in launching our clinical trials; changes in legislation;

inability to timely develop and introduce new technologies, products and

applications; lack of validation of our technology as we progress further and

lack of acceptance of our methods by the scientific community; inability to

retain or attract key employees whose knowledge is essential to the development

of our products; unforeseen scientific difficulties that may develop with our

process; greater cost of final product than anticipated; loss of market share

and pressure on pricing resulting from competition; and laboratory results that

do not translate to equally good results in real settings, all of which could

cause the actual results or performance to differ materially from those

contemplated in such forward-looking statements. Except as otherwise required

by law, Todos Medical does not undertake any obligation to publicly release any

revisions to these forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of

unanticipated events. For a more detailed description of the risks and

uncertainties affecting Todos Medical, please refer to its reports filed from

time to time with the U.S. Securities and Exchange Commission.

Todos Corporate and Investor


Richard Galterio

Todos Medical


Source link

The post Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button